PPLPHARMA PIRAMAL PHARMA LIMITED
Healthcare
LTP
239.32
CHG · %
+0.69 (+0.29%)
VOL · TODAY
28.53L
PREV CLOSE
238.63
Today's range235.12 · 240
239.32
52-week range132.3 · 243.2
239.32
Loading candles…
Piramal Pharma Limited entered the pharmaceutical industry in 1988 through the acquisition of Nicholas Laboratories. The company operates globally, offering end-to-end drug development and manufacturing solutions across several segments including Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG), and consumer healthcare. Its products and services encompass comprehensive drug development and manufacturing solutions. Piramal Pharma serves markets in India, North America, the UK/Europe, and over 100 other countries. The company has expanded through mergers, acquisitions, and organic growth, maintaining 17 development and manufacturing facilities. Notable transactions include the sale of its Domestic formulations business to Abbott in 2010 for $3.7 billion and the sale of its Diagnostic Services to Super Religare Laboratories (SRL). Approximately 70% of its revenue comes from regulated markets.
PPLPHARMA is not part of any active scan today.
This page is a live market overview for PIRAMAL PHARMA LIMITED (PPLPHARMA) on the NSE. As a listed security, PIRAMAL PHARMA LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for PPLPHARMA before placing trades on tick2trade.
As of the latest feed, PPLPHARMA last traded at ₹239.32 on NSE, up ₹0.69 (0.29%) from the previous close of ₹238.63. Today's session range is ₹235.12 – ₹240, against a 52-week band of ₹132.3 – ₹243.2. Traded volume today stands at 28.53L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for PPLPHARMA in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether PPLPHARMA is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for PIRAMAL PHARMA LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in PPLPHARMA. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated PPLPHARMA option chain page linked from this overview.
// similar in healthcare326 total